IHC market seen reaching $4.47 billion by 2030

The immunohistochemistry market is projected to grow from $3.05 billion in 2026 to $4.47 billion by 2030, according to a new report from The Business Research Company. Growth is being driven by cancer diagnostics, precision oncology, AI-powered pathology and broader use of biomarker-based testing.

Why it matters: - The immunohistochemistry market is tied directly to cancer diagnostics, precision oncology and tissue-based disease detection. - Faster adoption of automated staining, digital pathology and multiplex testing could change how pathology labs work and how quickly patients get answers.

What happened: - The Business Research Company released a 2026 market report on the global immunohistochemistry market. - The market was valued at $2.76 billion in 2025. - The market is projected to reach $3.05 billion in 2026. - The report forecasts the market will hit $4.47 billion by 2030. - The forecast implies a 10.1% compound annual growth rate from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Immunohistochemistry uses antibodies and antigens to identify specific proteins within tissue sections. - Detection can be chromogenic, using enzyme-substrate reactions, or fluorescent, using fluorescent dyes. - Recent growth has been driven by increased use of IHC in cancer diagnostics. - More hospital pathology labs have supported demand. - Greater access to monoclonal antibodies has expanded use. - Wider acceptance of tissue-based diagnostic methods has helped the market. - Clinical research activity has added to demand. - Future growth is expected to come from precision oncology diagnostics. - AI-powered pathology analysis is a major demand driver in the forecast. - Biomarker-driven drug discovery is expected to support market expansion. - Multiplex tissue profiling is gaining wider use. - Investment in advanced pathology infrastructure is increasing. - Notable trends include automated IHC staining systems, multiplex IHC methods, digital pathology platforms, companion diagnostic applications and high-specificity antibodies. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - A free sample of the report is available at the company’s sample page. - The full report is available at the company’s report page.

Between the lines: - Personalized medicine is a key reason the market is expanding. - IHC supports personalized care by detecting protein markers that help classify tumors and diagnose disease. - The Personalized Medicine Coalition reported in February 2024 that more than one-third of new FDA drug approvals in 2023 were personalized medicines. - The FDA approved 16 new personalized therapies for rare disease patients in 2023, up from 6 in 2022. - The regional split suggests the market is already mature in North America while growth momentum is shifting toward Asia-Pacific. - The emphasis on automation and digital tools signals a push for faster, more scalable pathology workflows.

What's next: - The market is likely to keep expanding as labs adopt more automated and AI-enabled diagnostic tools. - Companion diagnostics and multiplex testing are positioned to become more important in oncology workflows. - The report positions advanced pathology infrastructure as a key area for investment over the next several years.